24 May 2013
Keywords: sb, joins, merck, market, zocor, imminent, introduction
Article | 06 January 1992
With the imminent introduction of Merck & Co's HMG-CoA reductase
inhibitor hypolipemic Zocor (simvastatin) to the US market, SmithKline
Beecham has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 January 1992
23 May 2013
© 2013 thepharmaletter.com